MX2009012645A - Formulaciones y metodos para tratar el ojo seco. - Google Patents
Formulaciones y metodos para tratar el ojo seco.Info
- Publication number
- MX2009012645A MX2009012645A MX2009012645A MX2009012645A MX2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- dry eye
- formulations
- treating dry
- eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona composiciones para tratar y/o prevenir señales y síntomas asociados con el ojo seco y/o irritación ocular, y métodos para usar las mismas. Se proporcionan tales composiciones en formulaciones oftálmicas que producen bienestar en la aplicación gradual en los ojos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12480007P | 2007-05-24 | 2007-05-24 | |
US6615307P | 2007-06-18 | 2007-06-18 | |
US12480407P | 2007-08-02 | 2007-08-02 | |
PCT/US2008/006595 WO2008153746A1 (en) | 2007-05-24 | 2008-05-23 | Formulations and methods for treating dry eye |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012645A true MX2009012645A (es) | 2010-03-08 |
Family
ID=39737592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012645A MX2009012645A (es) | 2007-05-24 | 2008-05-23 | Formulaciones y metodos para tratar el ojo seco. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090010850A1 (es) |
EP (1) | EP2160182A1 (es) |
JP (1) | JP2010528014A (es) |
CN (1) | CN101754748A (es) |
AU (1) | AU2008262491A1 (es) |
CA (1) | CA2687717A1 (es) |
MX (1) | MX2009012645A (es) |
WO (1) | WO2008153746A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014046A2 (en) * | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
AU2009202969B1 (en) * | 2009-07-23 | 2009-11-19 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
US8778999B2 (en) * | 2009-03-05 | 2014-07-15 | Insite Vision Incorporated | Non-steroidal anti-inflammatory ophthalmic compositions |
EP2506831B1 (en) | 2009-12-03 | 2013-11-20 | Alcon Research, Ltd. | Carboxyvinyl polymer-containing nanoparticle suspensions |
EP3799866A1 (en) * | 2011-04-05 | 2021-04-07 | Optosolve Research & Development Ltd | Ophthalmic treatments comprising tramadol |
JP2013082682A (ja) * | 2011-09-29 | 2013-05-09 | Senju Pharmaceut Co Ltd | 亜塩素酸塩を含有する水性製剤 |
WO2014207769A1 (en) | 2013-06-27 | 2014-12-31 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
TWI670057B (zh) * | 2013-12-25 | 2019-09-01 | 日商日本股份有限公司Ltt生物醫藥 | 治療乾眼用滴眼劑 |
US20170051081A1 (en) * | 2014-05-02 | 2017-02-23 | Reliance Industries Limited | Apparatus for halogenation of polymer |
CN105030817A (zh) * | 2015-06-26 | 2015-11-11 | 江西禾氏美康药业有限公司 | 一种双组分复方右旋糖酐70滴眼液及其制备方法 |
WO2018033792A2 (en) | 2016-08-19 | 2018-02-22 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
CA3038528A1 (en) | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
CN111225687A (zh) * | 2017-09-01 | 2020-06-02 | 默里和普尔企业有限公司 | 用于治疗眼科疾患的方法和组合物 |
EP3687524A4 (en) * | 2017-09-28 | 2021-06-09 | Medicon Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS |
EP4368180A1 (en) * | 2021-07-09 | 2024-05-15 | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. | Application of loxoprofen sodium in preparation of drug for treating dry eye disease |
WO2024071349A1 (ja) * | 2022-09-29 | 2024-04-04 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体を含む配合剤 |
CN116473017B (zh) * | 2023-03-22 | 2024-01-05 | 首都医科大学附属北京同仁医院 | 基于小鼠泪腺诱导的干燥综合征小鼠模型的造模方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230724A (en) * | 1979-07-16 | 1980-10-28 | Allergan Pharmaceuticals, Inc. | Method of treating vascularization of the eye with Flurbiprofen |
US4407791A (en) * | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
DE3612537C1 (de) * | 1986-04-14 | 1987-07-16 | Dispersa Ag | Arzneimittel zur Behandlung von Entzuendungen im Auge |
US5110493A (en) * | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
US4910225A (en) * | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
US4960799A (en) * | 1988-09-13 | 1990-10-02 | Ciba-Geigy Corporation | Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use |
US5464609A (en) * | 1990-03-16 | 1995-11-07 | The Procter & Gamble Company | Use of ketorolac for treatment of oral diseases and conditions |
US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
US5603929A (en) * | 1994-11-16 | 1997-02-18 | Alcon Laboratories, Inc. | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
US5888493A (en) * | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
CN1229110C (zh) * | 1997-07-29 | 2005-11-30 | 阿尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
US6552020B1 (en) * | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
CA2477044A1 (en) * | 2002-02-22 | 2003-09-04 | Pharmacia Corporation | Ophthalmic formulation with gum system |
US6828356B2 (en) * | 2002-07-29 | 2004-12-07 | Ast Products, Inc. | Preparation of ophthalmic compositions |
US6806364B2 (en) * | 2002-07-29 | 2004-10-19 | Ast Products, Inc. | Ophthalmic compositions |
WO2004064828A1 (ja) * | 2003-01-21 | 2004-08-05 | Senju Pharmaceutical Co., Ltd. | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
US8008338B2 (en) * | 2003-06-03 | 2011-08-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US20050239745A1 (en) * | 2004-03-03 | 2005-10-27 | Ophthalmic Research Associates, Inc. | Novel topical ophthalmic formulations |
WO2005101982A2 (en) * | 2004-03-24 | 2005-11-03 | Sun Pharmaceutical Industries Limited | A stable ophthalmic composition |
TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
SI1885336T1 (sl) * | 2005-05-10 | 2009-08-31 | Alcon Inc | Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj |
US20070166402A1 (en) * | 2005-12-12 | 2007-07-19 | Friedlaender Mitchell H | Compositions, methods and kits for removing debris from an ocular area |
-
2008
- 2008-05-23 WO PCT/US2008/006595 patent/WO2008153746A1/en active Application Filing
- 2008-05-23 AU AU2008262491A patent/AU2008262491A1/en not_active Abandoned
- 2008-05-23 CA CA002687717A patent/CA2687717A1/en not_active Abandoned
- 2008-05-23 CN CN200880100031A patent/CN101754748A/zh active Pending
- 2008-05-23 US US12/154,665 patent/US20090010850A1/en not_active Abandoned
- 2008-05-23 EP EP08754683A patent/EP2160182A1/en not_active Withdrawn
- 2008-05-23 JP JP2010509393A patent/JP2010528014A/ja active Pending
- 2008-05-23 MX MX2009012645A patent/MX2009012645A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008262491A1 (en) | 2008-12-18 |
WO2008153746A1 (en) | 2008-12-18 |
US20090010850A1 (en) | 2009-01-08 |
CN101754748A (zh) | 2010-06-23 |
CA2687717A1 (en) | 2008-12-18 |
EP2160182A1 (en) | 2010-03-10 |
JP2010528014A (ja) | 2010-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012645A (es) | Formulaciones y metodos para tratar el ojo seco. | |
MX2011013060A (es) | Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. | |
WO2005076998A3 (en) | Rnai therapeutics for treatment of eye neovascularization diseases | |
WO2006105403A3 (en) | Treatment of eye disorders with sirtuin modulators | |
WO2006127987A3 (en) | Treatment of eye disorders with sirtuin modulators | |
WO2008029276A8 (en) | Compositions and methods for the treatment of ophthalmic disease | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
GEP20084520B (en) | Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases | |
TW200631605A (en) | Ophthalmic compositions and methods for treating eyes | |
MXPA06014470A (es) | Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas. | |
WO2007058935A3 (en) | Ophthalmic composition for dry eye therapy | |
MX2009009463A (es) | Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo. | |
JO3358B1 (ar) | معالجات حساسية العيون | |
EP4248971A3 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
MY172185A (en) | Artificial tears and therapeutic uses | |
JO2795B1 (en) | Immunoglobulins | |
PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
MY178169A (en) | Topical ophthalmic peptide formulation | |
CY1124538T1 (el) | Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης | |
ATE531703T1 (de) | Benzochromenderivate | |
MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
AR058141A1 (es) | Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas | |
UY28202A1 (es) | Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares. | |
WO2008136034A3 (en) | Ophthalmic compositions for the treatment of ocular hypertension and glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general |